When, How, and Why a Bone Biopsy Should Be Performed in Patients With Chronic Kidney Disease

Seminars in Nephrology

Volumn 34, Issue 6, 2014, Pages 612-625

  Torres, Pablo Ureña ^a   Bover, Jordi ^b   Mazzaferro, Sandro ^c   de Vernejoul, Marie Christine ^d   Cohen Solal, Martine ^d  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b FUNDACIÓ PUIGVERT   (Spain)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d CENTRE VIGGO PETERSEN   (France)

Author keywords

Adynamic bone disease; Aluminum; Bone biopsy; Chronic kidney disease; Hyperparathyroidism; Parathyroid hormone; Renal osteodystrophy

Indexed keywords

ALUMINUM; BISPHOSPHONIC ACID DERIVATIVE; BLOSOZUMAB; CADMIUM; CALCIMIMETIC AGENT; CALCIUM SALT; DEFEROXAMINE; DEMECLOCYCLINE; DENOSUMAB; DESMOPRESSIN; FLUORIDE; IRON; LANTHANUM; PARATHYROID HORMONE; ROMOSOZUMAB; STEROID; STRONTIUM; TETRACYCLINE; TRACE METAL; VITAMIN D; METAL;

AGE; BONE BIOPSY; BONE DISEASE; BONE REMODELING; BONE TURNOVER; CHEMICAL ANALYSIS; CHRONIC KIDNEY DISEASE; CLINICAL FEATURE; DIAGNOSTIC IMAGING; ETHNIC GROUP; FRACTURE; GENDER; GOLD STANDARD; HEMODIALYSIS; HISTOPATHOLOGY; HORMONE SYNTHESIS; HUMAN; NONHUMAN; OSTEOLYSIS; OSTEOPOROSIS; OUTCOME ASSESSMENT; QUALITY OF LIFE; RENAL OSTEODYSTROPHY; REVIEW; SECONDARY HYPERPARATHYROIDISM; ADVERSE EFFECTS; BIOPSY; BLOOD; BONE; CHEMISTRY; CHRONIC KIDNEY FAILURE; COMPLICATION; HYPERPARATHYROIDISM, SECONDARY; PATHOLOGY; PATIENT SELECTION; PREOPERATIVE CARE; PROCEDURES; RADIOGRAPHY;

BIOPSY; BONE AND BONES; BONE RESORPTION; HUMANS; HYPERPARATHYROIDISM, SECONDARY; METALS; PATIENT SELECTION; PREOPERATIVE CARE; RENAL INSUFFICIENCY, CHRONIC; RENAL OSTEODYSTROPHY;

EID: 84915733636     PISSN: 02709295     EISSN: 15584488     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2014.09.004     Document Type: Review

References (94)

1. Baron R. Anatomy and ultrastructure of bone. Primer on the metabolic bone diseases and disorders of mineral metabolism 1993, 3-9. Raven Press, Ltd, New York. 2nd ed. M.J. Favus (Ed.).
2. Vervloet M., Massy Z., Brandenburg V.M., et al. Bone: a new endocrine organ at the heart of chronic kidney disease and mineral disorders. Lancet Diabetes Endocrinol 2014, 2:427-436.
3. Termine J. Bone matrix proteins and the mineralization process. Primer on the metabolic bone diseases and disorders of mineral metabolism 1993, 21-25. Raven Press, Ltd, New York. 2nd ed. M.J. Favus (Ed.).
4. Yajima A., Inaba M., Tominaga Y., Ito A. Minimodeling reduces the rate of cortical bone loss in patients with secondary hyperparathyroidism. Am J Kidney Dis 2007, 49:440-451.
5. Bonewald L.F. Osteocyte biology: its implications for osteoporosis. J Musculoskelet Neuronal Interact 2004, 4:101-104.
6. Llach F., Bover J. Renal osteodystrophies. The kidney 2000, 2103-2186. W.B. Saunders Company, Philadelphia. 6th ed. B.M. Brenner (Ed.).
7. Kurz P., Monier-Faugere M.C., Bognar B., et al. Evidence for abnormal calcium homeostasis in patients with adynamic bone disease. Kidney Int 1994, 46:855-861.
8. Malluche H.H., Faugere M.C. Renal osteodystrophy. N Engl J Med 1989, 321:317-319.
9. Sebert J.L., Fardellone P., Noel C., et al. Bone biopsy studies in the diagnosis and treatment of renal osteodystrophy. Contrib Nephrol 1988, 64:49-57.
10. Cozzolino M., Urena-Torres P., Vervloet M.G., et al. Is chronic kidney disease-mineral bone disorder (CKD-MBD) really a syndrome?. Nephrol Dial Transplant 2014, 29(10):1815-1820.
11. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl 2009, 113:S1-130. KDIGO.
12. Moe S., Drueke T., Cunningham J., et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2006, 69:1945-1953.
13. Souberbielle J.C., Boutten A., Carlier M.C., et al. Inter-method variability in PTH measurement: implication for the care of CKD patients. Kidney Int 2006, 70:345-350.
14. Urena P. The need for a reliable serum parathyroid hormone measurements. Kidney Int 2006, 70:240-243.
15. Barreto F.C., Barreto D.V., Moyses R.M., et al. K/DOQI-recommended intact PTH levels do not prevent low-turnover bone disease in hemodialysis patients. Kidney Int 2008, 73:771-777.
16. Couttenye M.M., D'Haese P.C., VanHoof V.O., Lemoniatou E., Goodman W., DeBroe M.E. Bone alkaline phosphatase (BAP) compared to PTH in the diagnosis of adynamic bone disease (ABD) [abstract]. Nephrol Dial Transplant 1994, 9:905.
17. Urena P., Hruby M., Ferreira A., Ang K.S., de Vernejoul M.C. Plasma total versus bone alkaline phosphatase as markers of bone turnover in hemodialysis patients. J Am Soc Nephrol 1996, 7:506-512.
18. deVernejoul M., Kuntz D., Miravet L., Gueris J., Bielakoff J., Ryckewaert A. Bone histomorphometry in hemodialysed patients. Metab Bone Dis Relat Res 1981, 3:175-179.
19. Malluche H.H., Monier-Faugere M.C. The role of bone biopsy in the management of patients with renal osteodystrophy. J Am Soc Nephrol 1994, 4:1631-1642.
20. Frost H.M. Tetracycline-based histological analysis of bone remodeling. Calcif Tissue Res 1969, 3:211-237.
21. Parfitt A.M., Drezner M.K., Glorieux F.H., et al. Bone histomorphometry: standardization of nomenclature, symbols, and units. J Bone Miner Res 1987, 2:595-610.
22. Trueba D., Sawaya B.P., Mawad H., Malluche H.H. Bone biopsy: indications, techniques, and complications. Semin Dial 2003, 16:341-345.
23. Morris M.D., Mandair G.S. Raman assessment of bone quality. Clin Orthop Relat Res 2011, 469:2160-2169.
24. Dempster D.W., Compston J.E., Drezner M.K., et al. Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 2013, 28:2-17.
25. Christov M., Pereira R., Wesseling-Perry K. Bone biopsy in renal osteodystrophy: continued insights into a complex disease. Curr Opin Nephrol Hypertens 2013, 22:210-215.
26. Sherrard D., Baylink D., Wergedal J., Maloney N. Quantitative histological studies on the pathogenesis of uremic bone disease. J Clin Endocrinol Metab 1974, 39:119-135.
27. Rao S.D., Matkovic V., Duncan H. Transiliac bone biopsy. Complications and diagnostic value. Henry Ford Hosp Med J 1980, 28:112-115.
28. Maravic M., Ostertag A., Torres P.U., Cohen-Solal M. Incidence and risk factors for hip fractures in dialysis patients. Osteoporos Int 2014, 25:159-165.
29. Araujo S.M., Ambrosoni P., Lobao R.R., et al. The renal osteodystrophy pattern in Brazil and Uruguay: an overview. Kidney Int Suppl 2003, 85:S54-S56.
30. Piraino B., Chen T., Cooperstein L., Segre G., Puschett J. Fractures and vertebral bone mineral density in patients with renal osteodystrophy. Clin Nephrol 1988, 30:57-62.
31. Gerakis A., Hadjidakis D., Kokkinakis E., Apostolou T., Raptis S., Billis A. Correlation of bone mineral density with the histological findings of renal osteodystrophy in patients on hemodialysis. J Nephrol 2000, 13:437-443.
32. Andress D.L., Ott S.M., Maloney N.A., Sherrard D.J. Effect of parathyroidectomy on bone aluminum accumulation in chronic renal failure. N Engl J Med 1985, 312:468-473.
33. Slatopolsky E. The interaction of parathyroid hormone and aluminum in renal osteodystrophy. Kidney Int 1987, 31:842-854.
34. Yasuda H., Shima N., Nakagawa N., et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci U S A 1998, 95:3597-3602.
35. McCormick B.B., Davis J., Burns K.D. Severe hypocalcemia following denosumab injection in a hemodialysis patient. Am J Kidney Dis 2012, 60:626-628.
36. Chen C.L., Chen N.C., Hsu C.Y., et al. An open-label, prospective pilot clinical study of denosumab for severe hyperparathyroidism in patients with low bone mass undergoing dialysis. J Clin Endocrinol Metab 2014, 99:2426-2432.
37. Poole K.E., van Bezooijen R.L., Loveridge N., et al. Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J 2005, 19:1842-1844.
38. O'Brien C.A., Plotkin L.I., Galli C., et al. Control of bone mass and remodeling by PTH receptor signaling in osteocytes. PLoS One 2008, 3:e2942.
39. McClung M.R., Grauer A. Romosozumab in postmenopausal women with osteopenia. N Engl J Med 2014, 370:1664-1665.
40. McClung M.R., Grauer A., Boonen S., et al. Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med 2014, 370:412-420.
41. Sabbagh Y., Graciolli F.G., O'Brien S., et al. Repression of osteocyte Wnt/beta-catenin signaling is an early event in the progression of renal osteodystrophy. J Bone Miner Res 2012, 27:1757-1772.
42. Urena P., Ferreira A., Morieux C., Drueke T., de Vernejoul M.C. PTH/PTHrP receptor mRNA is down-regulated in epiphyseal cartilage growth plate of uraemic rats. Nephrol Dial Transplant 1996, 11:2008-2016.
43. Padhi D., Jang G., Stouch B., Fang L., Posvar E. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res 2011, 26:19-26.
44. Garnero P., Delmas P.D. Assessment of the serum levels of bone alkaline phosphatase with a new immunoradiometric assay in patients with metabolic bone disease. J Clin Endocrinol Metab 1993, 77:1046-1053.
45. Weiss M.J., Henthorn P.S., Lafferty M.A., Slaughter C., Raducha M., Harris H. Isolation and characterization of a cDNA encoding a human liver/bone/kidney-type alkaline phosphatase. Proc Natl Acad Sci U S A 1986, 84:7182-7186.
46. Weiss M.J., Junal R., Henthorn P.S., Kadesch T., Harris H. Structure of the human liver/bone/kidney-type alkaline phosphatase gene. J Biol Chem 1988, 263:12002-12010.
47. Seargeant L.E., Stinson R.A. Evidence that three structural genes code for human alkaline phosphatases. Nature 1979, 281:152-154.
48. Weiss M.J., Cole D.E., Ray K., et al. A missense mutation in the human liver/bone/kidney alkaline phosphatase gene causing a lethal form of hypophosphatasia. Proc Natl Acad Sci U S A 1988, 85:7666-7669.
49. Marie P.J., Lomri A., de Vernejoul M.C., et al. Relationships between histomorphometric features of bone formation and bone cell characteristics in vitro in renal osteodystrophy. J Clin Endocrinol Metab 1989, 69:1166-1173.
50. Fedde K.N., Michell M.P., Henthorn P.S., Whyte M.P. Aberrant properties of alkaline phosphatase in patient fibroblasts correlate with clinical expressivity in severe forms of hypophosphatasia. J Clin Endocrinol Metab 1996, 81:2587-2594.
51. Brossard J.H., Cloutier M., Roy L., Lepage R., Gascon-Barre M., D'Amour P. Accumulation of a non-(1-84) molecular form of parathyroid hormone (PTH) detected by intact PTH assay in renal failure: importance in the interpretation of PTH values. J Clin Endocrinol Metab 1996, 81:3923-3929.
52. Gagnon R.F., Pajel P., Kaye M. Hypophosphatemia-induced hypercalcemia during acute renal failure. Clin Exp Dial Apheresis 1983, 7:207-218.
53. Juppner H. Phosphate and FGF-23. Kidney Int Suppl 2011, 121:S24-S27.
54. Cabrera W.E., Schrooten I., De Broe M.E., D'Haese P.C. Strontium and bone. J Bone Miner Res 1999, 14:661-668.
55. D'Haese P.C., Couttenye M.M., Lamberts L.V., et al. Aluminum, iron, lead, cadmium, copper, zinc, chromium, magnesium, strontium, and calcium content in bone of end-stage renal failure patients. Clin Chem 1999, 45:1548-1556.
56. Mazzaferro S., Coen G., Ballanti P., et al. Deferoxamine test and PTH serum levels are useful not to recognize but to exclude aluminum-related bone disease. Nephron 1992, 61:151-157.
57. Malluche H.H. Aluminium and bone disease in chronic renal failure. Nephrol Dial Transplant 2002, 17(Suppl 2):21-24.
58. Malluche H.H., Mawad H. Management of hyperphosphataemia of chronic kidney disease: lessons from the past and future directions. Nephrol Dial Transplant 2002, 17:1170-1175.
59. Cohen-Solal M. Strontium overload and toxicity: impact on renal osteodystrophy. Nephrol Dial Transplant 2002, 17(Suppl 2):30-34.
60. Cohen-Solal M.E., Augry F., Mauras Y., Morieux C., Allain P., de Vernejoul M.C. Fluoride and strontium accumulation in bone does not correlate with osteoid tissue in dialysis patients. Nephrol Dial Transplant 2002, 17:449-454.
61. Noel C., Gosselin B., Dracon M., et al. [Risk of bone disease as a result of fluoride intake in chronic renal insufficiency]. Nephrologie 1985, 6:181-185.
62. Arnow P.M., Bland L.A., Garcia-Houchins S., Fridkin S., Fellner S.K. An outbreak of fatal fluoride intoxication in a long-term hemodialysis unit. Ann Intern Med 1994, 121:339-344.
63. Turner C.H., Takano Y., Hirano T. Reductions in bone strength after fluoride treatment are not reflected in tissue-level acoustic measurements. Bone 1996, 19:603-607.
64. Boivin G., Chavassieux P., Chapuy M.C., Baud C.A., Meunier P.J. Skeletal fluorosis: histomorphometric analysis of bone changes and bone fluoride content in 29 patients. Bone 1989, 10:89-99.
65. Mauras Y., Ang K.S., Simon P., Tessier B., Cartier F., Allain P. Increase in blood plasma levels of boron and strontium in hemodialyzed patients. Clin Chim Acta 1986, 156:315-320.
66. Marie P.J., Garba M.T., Hott M., Miravet L. Effect of low doses of stable strontium on bone metabolism in rats. Miner Electrolyte Metab 1985, 11:5-13.
67. Marie P.J., Hott M. Short-term effects of fluoride and strontium on bone formation and resorption in the mouse. Metabolism 1986, 35:547-551.
68. Marie P.J., Hott M., Modrowski D., et al. An uncoupling agent containing strontium prevents bone loss by depressing bone resorption and maintaining bone formation in estrogen-deficient rats. J Bone Miner Res 1993, 8:607-615.
69. Schrooten I., Cabrera W., Goodman W.G., et al. Strontium causes osteomalacia in chronic renal failure rats. Kidney Int 1998, 54:448-456.
70. D'Haese P.C., Schrooten I., Goodman W.G., et al. Increased bone strontium levels in hemodialysis patients with osteomalacia. Kidney Int 2000, 57:1107-1114.
71. Alfven T., Jarup L., Elinder C.G. Cadmium and lead in blood in relation to low bone mineral density and tubular proteinuria. Environ Health Perspect 2002, 110:699-702.
72. Jarup L. Cadmium overload and toxicity. Nephrol Dial Transplant 2002, 17(Suppl 2):35-39.
73. Staessen J.A., Roels H.A., Emelianov D., et al. Environmental exposure to cadmium, forearm bone density, and risk of fractures: prospective population study. Public Health and Environmental Exposure to Cadmium (PheeCad) Study Group. Lancet 1999, 353:1140-1144.
74. Alfven T., Elinder C.G., Hellstrom L., Lagarde F., Jarup L. Cadmium exposure and distal forearm fractures. J Bone Miner Res 2004, 19:900-905.
75. Malluche H.H., Siami G.A., Swanepoel C., et al. Improvements in renal osteodystrophy in patients treated with lanthanum carbonate for two years. Clin Nephrol 2008, 70:284-295.
76. Fraile P., LMG-C Cacharro, Rosado P., Matias C., Tabernero J. Encephalopathy caused by lanthanum carbonate. NDT Plus 2011, 4:192-194.
77. Hutchison A.J., Barnett M.E., Krause R., Siami G.A. Lanthanum carbonate treatment, for up to 6 years, is not associated with adverse effects on the liver in patients with chronic kidney disease stage 5 receiving hemodialysis. Clin Nephrol 2009, 71:286-295.
78. Behets G.J., Dams G., Vercauteren S.R., et al. Does the phosphate binder lanthanum carbonate affect bone in rats with chronic renal failure?. J Am Soc Nephrol 2004, 15:2219-2228.
79. Behets G.J., Verberckmoes S.C., D'Haese P.C., De Broe M.E. Lanthanum carbonate: a new phosphate binder. Curr Opin Nephrol Hypertens 2004, 13:403-409.
80. Bervoets A.R., Spasovski G.B., Behets G.J., et al. Useful biochemical markers for diagnosing renal osteodystrophy in predialysis end-stage renal failure patients. Am J Kidney Dis 2003, 41:997-1007.
81. D'Haese P., Damment S.J. Comment on 'Lanthanum deposition in a dialysis patient'. Nephrol Dial Transplant 2010, 25:314. (author reply, 6).
82. Cannata J.B., Fernandez-Martin J.L., Diaz-Lopez B., et al. Influence of iron status in the response to the deferoxamine test. J Am Soc Nephrol 1996, 7:135-139.
83. Black D., Duncan A., Robins S.P. Quantitative analysis of the pyridinium crosslinks of collagen in urine using ion-paired reversed-phase high-performance liquid chromatography. Anal Biochem 1988, 169:197-203.
84. Black D.M., Cummings S.R., Genant H.K., Nevitt M.C., Palermo L., Browner W. Axial and appendicular bone density predict fractures in older women. J Bone Miner Res 1992, 7:633-638.
85. Urena P., Bernard-Poenaru O., Ostertag A., et al. Bone mineral density, biochemical markers and skeletal fractures in haemodialysis patients. Nephrol Dial Transplant 2003, 18:2325-2331.
86. Taal M.W., Cassidy M.J., Pearson D., Green D., Masud T. Usefulness of quantitative heel ultrasound compared with dual-energy X-ray absorptiometry in determining bone mineral density in chronic haemodialysis patients. Nephrol Dial Transplant 1999, 14:1917-1921.
87. Taal M.W., Masud T., Green D., Cassidy M.J. Risk factors for reduced bone density in haemodialysis patients. Nephrol Dial Transplant 1999, 14:1922-1928.
88. Julian B.A., Faugere M.C., Malluche H.H. Oxalosis in bone causing a radiographical mimicry of renal osteodystrophy. Am J Kidney Dis 1987, 9:436-440.
89. Goodman W.G., Goldin J., Kuizon B.D., et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000, 342:1478-1483.
90. Raggi P., Ali O. Phosphorus restriction and control of coronary calcification as assessed by electron beam tomography. Curr Opin Nephrol Hypertens 2002, 11:391-395.
91. Urena-Torres P.A., Floege J., Hawley C.M., et al. Protocol adherence and the progression of cardiovascular calcification in the ADVANCE study. Nephrol Dial Transplant 2013, 28:146-152.
92. London G.M., Guerin A.P., Marchais S.J., Metivier F., Pannier B., Adda H. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 2003, 18:1731-1740.
93. Shigematsu T., Kazama J.J., Yamashita T., et al. Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency. Am J Kidney Dis 2004, 44:250-256.
94. Quarles L.D. FGF23, PHEX, and MEPE regulation of phosphate homeostasis and skeletal mineralization. Am J Physiol Endocrinol Metab 2003, 285:E1-E9.